Avastin shows good results in colon cancer patients
Chicago, June 8: Colorectal cancer patients treated with a follow-up round of Avastin fare better than those given chemotherapy alone after their disease has worsened, according to results of a large clinical trial.
Avastin, sold by Roche, is approved as a first-line or second-line treatment for colorectal cancer, but not for both. Sales of the drug, also known as bevacizumab, totaled $5.3 billion Swiss francs ($5.5 billion) last year.
"By simply switching chemotherapy drugs when the cancer progresses and continuing with bevacizumab, we can make second-line treatment even more powerful," said Dr. Dirk Arnold, director of Germany's Hubertus Wald Tumor Center of University Cancer Center Hamburg, and a trial investigator.
First-line treatment is initial treatment, while second-line treatment occurs after cancer starts showing signs of progression.
Avastin is an antibody that blocks vascular endothelial growth factor, or VEGF, a protein tumors need to grow nutrient-providing blood vessels. It is approved in the United States for treating glioblastoma, colorectal, lung and kidney cancers.
"A fundamental feature and importance of this study is that it does confirm our hypothesis that continuing to inhibit VEGF throughout the lifetime of a tumor can reduce its growth and survival," said Sandra Horning, head of global development at Roche's Genentech unit.
The Phase III study involved 820 patients with metastatic, inoperable colorectal cancer who had been treated with standard first-line chemotherapy and Avastin. Once their disease worsened, they were randomized to receive either Avastin and a different chemo drug, or the chemo drug and a placebo.
Patients in the Avastin group lived for a median of 11.2 months, compared with 9.8 months for the chemotherapy-alone group. The research was presented on Sunday at a meeting of the American Society of Clinical Oncology.
Genentech said some doctors were already using Avastin as a follow-up regimen for colon cancer patients who had relapsed, and it is talking with regulators about changing the drug's label to include the latest findings.
Lastupdate on : Fri, 8 Jun 2012 21:30:00 Makkah time
Lastupdate on : Fri, 8 Jun 2012 18:30:00 GMT
Lastupdate on : Sat, 9 Jun 2012 00:00:00 IST
- MORE FROM HEALTH
‘Govt committed to holistic development of JK’
GK NEWS NETWORK
Srinagar, June 8: Chief Minister Omar Abdullah Friday said that “equitable development of J&K is my government’s commitment and a holistic roadmap is being followed to reach out to all areas and all More
- Srinagar City
Compactors to carry multiple truckloads in one go; KHARA, KHROF hail sanitation novelty on Boulevard
GK CITY REPORTER
Srinagar, June 8: At a time when Nano Technology is going trendy, something of the sort has embedded the City at least with regard to garbage collection. The loosely loaded trucks of garbage ferrying trash More
Jammu, June 8: Jammu and Kashmir government has sought Rs 700 crore assistance under Prime Minister’s Reconstruction Plan (PMRP) - a Union Home Ministry funded programme in the state – for the current More
‘We are fighting Pakistan’s war’
REZAUL H LASKAR/PTI
Islamabad, June 8: Hizb-ul-Mujahideen chief Syed Salahuddin has vowed to turn the guns on Pakistan if it stops backing Kashmiri militants who, he said, were fighting “Pakistan's war”. “We are fighting More
London, June 8: Employees with better promotion prospects are 20 percent less likely to suffer heart disease than those with slender chances of improving their situation. So says a study conducted More
- Education and Career
Charity Show Concludes At Islamic University
Srinagar, June 8: The Government is contemplating to start short term winter courses and summer courses both in Srinagar and Jammu provinces during winter and summer vacations for ensuring better utilization More